Findings

What do systematic reviews say?

32 questions · 36 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 8.3%GRADE not reported 23 · 63.9%Very low 3 · 8.3%Low 7 · 19.4%Moderate 0 · 0%High 0 · 0%

Amifostine (intravenous) vs Amifostine (subcutaneous)

Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No salivary flow rate data related to routes of administration of amifostine were reported.
0 studies
No studies found

Amifostine (intravenous) vs Amifostine (subcutaneous)

Adverse effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Increased hypotension with intravenous delivery (20% vs 8%; P = 0.007); skin rash (10% vs 22%; P = 0.012) and local pain at injection site (0% vs 8%; P = 0.001) worse with subcutaneous; inconclusive for…
1 study
GRADE not reported

Amifostine (intravenous) vs Amifostine (subcutaneous)

Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine (intravenous) showed no clear difference in overall survival compared with amifostine (subcutaneous); GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
48 months postRT
HR 1.36 [0.89, 2.10]
1 study
GRADE not reported

Amifostine (intravenous) vs Amifostine (subcutaneous)

Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No data on either quality of life or other oral related symptoms were reported.
0 studies
No studies found

Amifostine (intravenous) vs Amifostine (subcutaneous)

Xerostomia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine (intravenous) led to lower xerostomia (grade >= 2, 0-4 scale) compared with amifostine (subcutaneous); GRADE not reported.

2 findings from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
12 months postRT
RR 0.61 [0.42, 0.88]
1 study · 127 participants
GRADE not reported
Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Up to and including 3 months postRT
RR 1.03 [0.76, 1.40]
1 study · 263 participants
GRADE not reported

Amifostine 200 mg/m2 three times weekly vs Amifostine 200 mg/m2 five times weekly

Survival (overall survival and locoregional control) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Insufficient evidence reported on overall survival or locoregional tumour control (Analysis 4.2; 4.3)
1 study
GRADE not reported

Amifostine 200 mg/m2 three times weekly vs Amifostine 200 mg/m2 five times weekly

Allergic adverse events · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine 200 mg/m2 three times weekly showed no clear difference in allergic response (adverse effect) compared with amifostine 200 mg/m2 five times weekly; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
RR 1.00 [0.15, 6.64]
1 study · 60 participants
GRADE not reported

Amifostine 200 mg/m2 three times weekly vs Amifostine 200 mg/m2 five times weekly

Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No salivary flow rate data related to the effectiveness of different doses of amifostine were reported.
0 studies
No studies found

Amifostine 200 mg/m2 three times weekly vs Amifostine 200 mg/m2 five times weekly

Nausea · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine 200 mg/m2 three times weekly showed no clear difference in nausea (adverse effect) compared with amifostine 200 mg/m2 five times weekly; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
RR 0.64 [0.33, 1.25]
1 study · 60 participants
GRADE not reported

Amifostine 200 mg/m2 three times weekly vs Amifostine 200 mg/m2 five times weekly

Xerostomia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine 200 mg/m2 three times weekly showed no clear difference in xerostomia (grade >= 2, 0-4 scale) compared with amifostine 200 mg/m2 five times weekly; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
12 months postRT
RR 0.94 [0.58, 1.53]
1 study · 49 participants
GRADE not reported

Amifostine 200 mg/m2 three times weekly vs Amifostine 200 mg/m2 five times weekly

Vomiting · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine 200 mg/m2 three times weekly showed no clear difference in vomiting (adverse effect) compared with amifostine 200 mg/m2 five times weekly; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
RR 0.25 [0.06, 1.08]
1 study · 60 participants
GRADE not reported

Amifostine 200 mg/m2 three times weekly vs Amifostine 200 mg/m2 five times weekly

Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
End of RT and 6, 12, 18, 24 months postRT
No significant differences between the three treatment arms (Jellema 2006)
1 study
GRADE not reported